Regeneron begins clinical trials for COVID-19 antibody treatment

By The Science Advisory Board staff writers

June 12, 2020 -- Regeneron Pharmaceuticals has started its first clinical trial investigating an antibody treatment for COVID-19.

REGN-COV2 is an "antibody cocktail" designed to help prevent and treat COVID-19, the disease caused by the novel coronavirus, according to the company. Regeneron will test its therapeutic on four distinct study populations:

  • Hospitalized patients with COVID-19
  • Symptomatic but not hospitalized patients with COVID-19
  • People without COVID-19 who have a high risk of exposure, including healthcare workers
  • People without COVID-19 who have close exposure to a confirmed case, such as living with a family member or housemate who has COVID-19

For its therapeutic agent, Regeneron selected promising, noncompeting antibodies found through testing people who have recovered from COVID-19 and mice that have been genetically modified to have human immune systems. The two selected antibodies work together to bind to the SARS-CoV-2 receptor-binding domain on the spike protein, diminishing its viral ability. Production of the neutralizing antibodies for clinical use was done with the company's VelociMab and manufacturing capabilities.

The REGN-COV2 trial is being partly funded by the U.S. Biomedical Advanced Research and Development Authority. The company used a similar approach when developing a triple antibody treatment for Ebola, which is currently being reviewed by the U.S. Food and Drug Administration.

NIH researchers investigate virulence of SARS-CoV-2 virus
What makes the SARS-CoV-2 virus so virulent? Researchers from the U.S. National Institutes of Health (NIH) analyzed the genomics of the virus -- and compared...
Manufacturers adapt technologies for hand sanitizers during COVID-19
Changes to manufacturing processes have emerged to meet the demand of certain products during the COVID-19 pandemic, including hand sanitizer. The chemical...
How will summer weather shape the spread of COVID-19?
New research shows that while higher temperatures and humidity can slow the spread of COVID-19, longer hours of sunlight are associated with a higher...
Transparency helps maintain scientific integrity of clinical trials
A new study offers reassuring evidence about the integrity of registered clinical trials, with researchers finding no signs of widespread manipulation...
FDA researchers explore vaccine responses to SARS-CoV-2 antigens
Different proteins associated with SARS-CoV-2, the virus that causes COVID-19, generate unique immune responses when given to rabbits as immunizations,...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter